Completed Chemistry Genetics & Molecular Biology

SynthSys-Mammalian: Edinburgh Mammalian Synthetic Biology Research Centre

In plain English

AI plain-English summary

Synthetic biology is being engineered into mammalian cells to turn them into programmable biological machines. The Edinburgh Centre for Mammalian Synthetic Biology aims to build the core tools—such as computer-designed DNA, whole-cell computer models, and high-throughput cell testing—that will allow researchers to treat mammalian cells like engineered systems, not just natural organisms. This matters because synthetic biology has largely focused on bacteria and yeast, leaving mammalian cells—which are far more complex and medically relevant—largely untouched by engineering principles. Without these tools, scientists cannot reliably design mammalian cells to perform specific tasks. If the centre succeeds, the impact could be broad: pharmaceutical companies could use engineered cells to test drugs more accurately, biosensor cell lines could detect disease biomarkers for early diagnostics, and new protein-based drugs such as antibodies could be produced more efficiently. In regenerative medicine, the tools could help program stem cells to develop into specific tissues. The centre will also study the social and economic implications of the technology to guide its responsible use.

View original technical description
The vision for Edinburgh's Centre for Mammalian Synthetic Biology (SynthSys-Mammalian) is to pioneer the development of the underpinning tools and technologies needed to implement engineering principles and realise the full potential of synthetic biology in mammalian systems. We have an ambitious plan to build in-house expertise in cell engineering tool generation, whole-cell modelling, computer-assisted design and construction of DNA and high-throughput phenotyping to enable synthetic biology in mammalian systems for multiple applications. In this way we will not only advance basic understanding of mammalian biology but also generate tools and technologies for near-term commercial exploitation in areas such as the pharmaceutical and drug testing industries, biosensing cell lines sensing disease biomarkers for diagnositics, novel therapeutics, production of protein based drugs e.g. antibodies and also programming stem cell development and differentiation for regenerative medicine applications. In parallel we will develop and implement new understanding of the social and economic impact of this far-reaching technology to ensure its benefits to society.

View the original record at the funder ↗

Researchers

Adrian Bird (Co-Investigator)Alistair Elfick (Co-Investigator)Andrew Millar (Co-Investigator)Charles Ffrench-Constant (Co-Investigator)Emma Frow (Co-Investigator)Jamie Davies (Co-Investigator)Jane Calvert (Co-Investigator)Joyce Tait (Co-Investigator)Nacho Molina (Co-Investigator)Peter Swain (Co-Investigator)Steven Pollard (Co-Investigator)Susan Rosser (Principal Investigator)Teuta Pilizota (Co-Investigator)Vincent Danos (Co-Investigator)William Charles Earnshaw (Co-Investigator)Yizhi Cai (Co-Investigator)

Related Research

Grants with similar aims, by meaning.

Promoters for Improved Protein & Biopharmaceutics Production in Mammalian Cells
Enabling Tools & Technologies for Synthetic Biology
Synthetic Portabolomics: Leading the way at the crossroads of the Digital and the Bio Economies
Engineering Autophagy: Understanding Cellular Decommissioning Using Synthetic Biology
'Synbion' The UCL Network in Synthetic Biology

Original classification

Research Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.